MedPath

Suzhou Ribo Life Science Co., Ltd.

Suzhou Ribo Life Science Co., Ltd. logo
🇨🇳China
Ownership
Holding
Established
2007-01-18
Employees
51
Market Cap
-
Website
http://www.ribolia.com

A Study of RBD1016 in CHB Participants

Phase 2
Active, not recruiting
Conditions
Chronic Hepatitis B
Interventions
First Posted Date
2023-07-27
Last Posted Date
2024-12-05
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
48
Registration Number
NCT05961098
Locations
🇨🇳

Prince of Wales Hospital, Hong Kong, China

🇨🇳

Queen Mary Hospital, Hong Kong, China

🇸🇪

Karolinska University Hospital, Stockholm, Sweden

and more 1 locations

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Phase 1
Completed
Conditions
Hyperlipemia
Interventions
Drug: Placebo
First Posted Date
2023-06-22
Last Posted Date
2025-05-01
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
80
Registration Number
NCT05912296
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

Phase 1
Active, not recruiting
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2022-12-16
Last Posted Date
2024-12-03
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
32
Registration Number
NCT05653037
Locations
🇦🇺

Q-Pharm Pty Limited, Brisbane, Australia

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

Phase 1
Completed
Conditions
Health Volunteer
Interventions
Drug: Placebo
First Posted Date
2022-09-14
Last Posted Date
2024-12-04
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
72
Registration Number
NCT05539651
Locations
🇦🇺

Q-Pharm Pty Limited, Brisbane, Australia

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

Phase 1
Completed
Conditions
Chronic Hepatitis B
Interventions
First Posted Date
2021-08-23
Last Posted Date
2024-12-06
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
40
Registration Number
NCT05017116
Locations
🇨🇳

The University of Hong Kong, Hong Kong, China

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2020-12-28
Last Posted Date
2022-04-26
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
32
Registration Number
NCT04685564
Locations
🇦🇺

Scientia Clinical Research Ltd, Randwick, Australia

© Copyright 2025. All Rights Reserved by MedPath